Sulbactam and Durlobactam is indicated for:
Population group: only adults (18 years old or older)
Sulbactam/durlobactam combination is indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulbactam/durlobactam and other antibacterial drugs, sulbactam/durlobactam should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Sulbactam and Durlobactam is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
